Trials / Unknown
UnknownNCT03955354
PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
A Phase II Study of PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
the investigators launched this exploratory study to evaluate the objective response rate (ORR) of SHR-1210 combined with apatinib mesylate in the first-line treatment of patients with advanced acral melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR1210 | SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody |
| DRUG | apatinib mesylate | apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2). |
Timeline
- Start date
- 2019-03-05
- Primary completion
- 2020-04-10
- Completion
- 2021-04-10
- First posted
- 2019-05-20
- Last updated
- 2019-05-20
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03955354. Inclusion in this directory is not an endorsement.